Logo image of SSKN

STRATA SKIN SCIENCES INC (SSKN) Stock Fundamental Analysis

USA - NASDAQ:SSKN - US86272A3059 - Common Stock

1.89 USD
-0.19 (-9.13%)
Last: 10/17/2025, 8:00:00 PM
1.9 USD
+0.01 (+0.53%)
After Hours: 10/17/2025, 8:00:00 PM
Fundamental Rating

1

SSKN gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. SSKN may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, SSKN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SSKN had negative earnings in the past year.
In the past year SSKN has reported a negative cash flow from operations.
In the past 5 years SSKN always reported negative net income.
In multiple years SSKN reported negative operating cash flow during the last 5 years.
SSKN Yearly Net Income VS EBIT VS OCF VS FCFSSKN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M

1.2 Ratios

SSKN has a Return On Assets of -37.56%. This is in the lower half of the industry: SSKN underperforms 60.73% of its industry peers.
The Return On Equity of SSKN (-3746.75%) is worse than 90.05% of its industry peers.
Industry RankSector Rank
ROA -37.56%
ROE -3746.75%
ROIC N/A
ROA(3y)-21.43%
ROA(5y)-15.91%
ROE(3y)-104.54%
ROE(5y)-68.27%
ROIC(3y)N/A
ROIC(5y)N/A
SSKN Yearly ROA, ROE, ROICSSKN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

With a Gross Margin value of 57.89%, SSKN perfoms like the industry average, outperforming 57.07% of the companies in the same industry.
SSKN's Gross Margin has declined in the last couple of years.
SSKN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.95%
GM growth 5Y-2.39%
SSKN Yearly Profit, Operating, Gross MarginsSSKN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

0

2. Health

2.1 Basic Checks

SSKN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SSKN has been increased compared to 1 year ago.
SSKN has less shares outstanding than it did 5 years ago.
The debt/assets ratio for SSKN is higher compared to a year ago.
SSKN Yearly Shares OutstandingSSKN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SSKN Yearly Total Debt VS Total AssetsSSKN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -10.95, we must say that SSKN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -10.95, SSKN is doing worse than 82.72% of the companies in the same industry.
A Debt/Equity ratio of 49.58 is on the high side and indicates that SSKN has dependencies on debt financing.
SSKN's Debt to Equity ratio of 49.58 is on the low side compared to the rest of the industry. SSKN is outperformed by 90.58% of its industry peers.
Industry RankSector Rank
Debt/Equity 49.58
Debt/FCF N/A
Altman-Z -10.95
ROIC/WACCN/A
WACC10.06%
SSKN Yearly LT Debt VS Equity VS FCFSSKN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

A Current Ratio of 0.98 indicates that SSKN may have some problems paying its short term obligations.
The Current ratio of SSKN (0.98) is worse than 89.01% of its industry peers.
SSKN has a Quick Ratio of 0.98. This is a bad value and indicates that SSKN is not financially healthy enough and could expect problems in meeting its short term obligations.
SSKN's Quick ratio of 0.75 is on the low side compared to the rest of the industry. SSKN is outperformed by 85.34% of its industry peers.
Industry RankSector Rank
Current Ratio 0.98
Quick Ratio 0.75
SSKN Yearly Current Assets VS Current LiabilitesSSKN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for SSKN have decreased strongly by -16.87% in the last year.
The Revenue has been growing slightly by 0.36% in the past year.
The Revenue has been growing slightly by 1.22% on average over the past years.
EPS 1Y (TTM)-16.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1900%
Revenue 1Y (TTM)0.36%
Revenue growth 3Y3.83%
Revenue growth 5Y1.22%
Sales Q2Q%-9.15%

3.2 Future

The Earnings Per Share is expected to grow by 28.30% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 4.04% on average over the next years.
EPS Next Y37.76%
EPS Next 2Y28.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-1.34%
Revenue Next 2Y4.04%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SSKN Yearly Revenue VS EstimatesSSKN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M
SSKN Yearly EPS VS EstimatesSSKN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SSKN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SSKN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SSKN Price Earnings VS Forward Price EarningsSSKN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SSKN Per share dataSSKN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

SSKN's earnings are expected to grow with 28.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.3%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SSKN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STRATA SKIN SCIENCES INC

NASDAQ:SSKN (10/17/2025, 8:00:00 PM)

After market: 1.9 +0.01 (+0.53%)

1.89

-0.19 (-9.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-11 2025-11-11/amc
Inst Owners29.88%
Inst Owner Change0%
Ins Owners3.09%
Ins Owner Change0%
Market Cap9.96M
Analysts85
Price Target8.16 (331.75%)
Short Float %2.82%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-57.4%
Min EPS beat(2)-104.6%
Max EPS beat(2)-10.2%
EPS beat(4)0
Avg EPS beat(4)-101.01%
Min EPS beat(4)-271.14%
Max EPS beat(4)-10.2%
EPS beat(8)2
Avg EPS beat(8)-96.62%
EPS beat(12)4
Avg EPS beat(12)-54.24%
EPS beat(16)7
Avg EPS beat(16)-36.31%
Revenue beat(2)0
Avg Revenue beat(2)-10.27%
Min Revenue beat(2)-12.25%
Max Revenue beat(2)-8.28%
Revenue beat(4)2
Avg Revenue beat(4)-3.72%
Min Revenue beat(4)-12.25%
Max Revenue beat(4)4.61%
Revenue beat(8)3
Avg Revenue beat(8)-5.92%
Revenue beat(12)5
Avg Revenue beat(12)-3.01%
Revenue beat(16)7
Avg Revenue beat(16)-1.73%
PT rev (1m)0%
PT rev (3m)-11.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-70.8%
EPS NY rev (1m)0%
EPS NY rev (3m)-35.49%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.3
P/FCF N/A
P/OCF N/A
P/B 32.34
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.84
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS6.23
BVpS0.06
TBVpS-1.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.56%
ROE -3746.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.89%
FCFM N/A
ROA(3y)-21.43%
ROA(5y)-15.91%
ROE(3y)-104.54%
ROE(5y)-68.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.95%
GM growth 5Y-2.39%
F-Score3
Asset Turnover1.07
Health
Industry RankSector Rank
Debt/Equity 49.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.87%
Cap/Sales 2.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.98
Quick Ratio 0.75
Altman-Z -10.95
F-Score3
WACC10.06%
ROIC/WACCN/A
Cap/Depr(3y)63.47%
Cap/Depr(5y)69.64%
Cap/Sales(3y)9.91%
Cap/Sales(5y)10.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1900%
EPS Next Y37.76%
EPS Next 2Y28.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)0.36%
Revenue growth 3Y3.83%
Revenue growth 5Y1.22%
Sales Q2Q%-9.15%
Revenue Next Year-1.34%
Revenue Next 2Y4.04%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year114.9%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y54.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.81%
OCF growth 3Y-50.07%
OCF growth 5Y-39.02%